Treatment of cystic fibrosis related bone disease

Jagdeesh Ullal a,1,*, Katherine Kutney b,2, Kristen M. Williams c,3, David R. Weber d

a UPMC Center for Diabetes and Endocrinology, University of Pittsburgh Medical Center, 3601 Fifth Ave, Suite 3B, Falk Medical Building, Pittsburgh, PA 15213, USA
b Pediatric Endocrinology, Rainbow Babies and Children’s Hospital, 11100 Euclid Ave, Suite 737, Cleveland, OH 44106, USA
c Naomi Berrie Diabetes Center, Columbia University Irving Medical Center Division of Pediatric Endocrinology, Diabetes, and Metabolism, Columbia University Irving Medical Center, 1150 St Nicholas Avenue, New York, NY 10032, USA
d Division of Pediatric Endocrinology & Diabetes & Center for Bone Health, The Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania Roberts Clinical Research Bldg., Room 14361 415 Curie Boulevard, Philadelphia, PA 19104, USA

A R T I C L E   I N F O
Keywords:
Cystic fibrosis bone disease
Bone density
Cystic fibrosis
Bisphosphonates
Bone density screening

A B S T R A C T

The advent of highly effective CFTR modulator therapies has slowed the progression of pulmonary complications in people with cystic fibrosis. There is increased interest in cystic fibrosis bone disease (CFBD) due to the increasing longevity of people with cystic fibrosis. CFBD is a complex and multifactorial disease. CFBD is a result of hypomineralized bone leading to poor strength, structure and quality leading to susceptibility to fractures. The development of CFBD spans different age groups. The management must be tailored to each group with nuance and based on available guidelines while balancing therapeutic benefits to risks of long-term use of bone-active medication. For now, the mainstay of treatment includes bisphosphonates. However, the long-term effects of bisphosphonate treatment in people with CF are not fully understood. We describe newer agents available for osteoporosis treatment. Still, the lack of data behooves trials of monoclonal antibodies treatments such as Denosumab and Romozosumab and anabolic bone therapy such as teriparatide and Abaloparatide. In this review, we also summarize screening and non-pharmacologic treatment of CFBD and describe the various options available for the pharmacotherapy of CFBD. We address the prospect of CFTR modulators on bone health while awaiting long-term trials to describe the effects of these medications on bone health.

Introduction

Highly effective CFTR modulator therapy is linked with improved quality of life and longer life expectancy in people with cystic fibrosis [1,2]. It is expected that the pulmonary disease burden will lessen but other chronic complications such as cystic fibrosis bone disease (CFBD) may add to a higher morbidity associated with CF in the form of fractures, pain and disability. The pathophysiology of CFBD is multifactorial and poorly understood [3]. The treatments vary through different stages of life and must contend with balancing therapeutic benefit over long-term adverse effects. In this review, we summarize the non-pharmacologic and pharmacologic therapies for CFBD across various stages of life for people with CF (PCF).

Bone health screening

Bone mineral content accrual is highest during childhood and adolescence and impaired bone modeling during this time can have a significant impact on bone health in adulthood. Dual-energy x-ray absorptiometry (DXA) is the gold standard imaging tool for clinical assessment for bone health in children and adults, measuring both bone mineral content (BMC) and area bone mineral density (aBMD). Low BMD, defined by DXA-derived height and age adjusted Z-scores of less than or equal to –2.0 standard deviations (SD), has been reported between 9 and 32% in children and adolescents with CF [4–6] and is associated with low BMI, low vitamin D levels, and higher disease severity scores [6]. Osteoporosis in this age group can be diagnosed by

* Corresponding author at: UPMC Center for Diabetes and Endocrinology, Falk Medical Building, 3601 Fifth Ave Suite 3B, Pittsburgh, PA 15213, USA. Tel.: 412-586-9700; Fax: 412-586-9724.
E-mail addresses: ullalj@upmc.edu (J. Ullal), Katherine.kutney@uhhospitals.org (K. Kutney), kmw2160@cumc.columbia.edu (K.M. Williams), weberd@chop.edu (D.R. Weber).

1 This work was supported by the Cystic Fibrosis Foundation EnVision-II CF: Emerging Leaders in CF Endocrinology grant number ULLAL19GE0.
2 This work was supported by the Cystic Fibrosis Foundation EnVision-II CF: Emerging Leaders in CF Endocrinology grant number KUTNEY19GE0.
3 This work was supported by the Cystic Fibrosis Foundation EnVision-II CF: Emerging Leaders in CF Endocrinology grant number WILLIA19GE0.

https://doi.org/10.1016/j.jcte.2021.100291
Received 31 August 2021; Received in revised form 3 December 2021; Accepted 4 December 2021
Available online 21 December 2021
2214-6237/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(https://creativecommons.org/licenses/by-nc-nd/4.0/).
low BMD with long bone fractures (up to 2 fractures by age 10 or 3 fractures by age 19) or by the presence of a vertebral fragility fracture, independent of Z-score BMD [7]. Small cross-sectional studies report an increased risk of vertebral and rib fracture compared to healthy children and teens [8]. Fracture risk assessment remains limited in this age group, however, current guidelines are available to assist in directing the initiation and monitoring of non-pharmacologic and pharmacologic therapies [9]. Screening, risk stratification and treatment guidelines are offered by the Cystic Fibrosis Foundation (CFF), European, French, and Australian groups for children and adults with CF and are summarized in Table 1 [6,10,11].

In adults with CF, screening for CFBD starts at age 18 based on CFF guidelines. The French, European and CFF guidelines recommend DXA screening of children>8 years with significant risk factors for bone disease [11]. The CFF, European and French guidelines for screening [6,10] recommend screening based on T-score and Z-scores > −1 SD: every 5 years; ≤−1 SD and > −2.5 SD, every 2 years and ≤−2 SD every year with the European guidelines recommending screening every year if scores are ≤ 2.5 SD or the presence of low trauma fractures. High risk groups are identified as PCF with low trauma fractures, Z-scores of less than −2 SD at the spine with a rapid bone loss of > 4% per year, candidates awaiting lung transplantation or with use of high dose steroids. There are no CF-specific guidelines for postmenopausal osteoporosis and men over 50 years. The National Osteoporosis Foundation guidelines are not CF specific but offer recommendations for this age group [12].

**Nonpharmacological therapy**

**Role of minimizing respiratory exacerbations in improving bone health**

Non-pharmacological treatments may be effective for preventing CF bone disease and often align with other health priorities. For example, minimizing pulmonary exacerbations is advantageous for CF lung disease as well as likely protective against CF bone disease. CF pulmonary exacerbations are temporally associated with elevated inflammatory markers IL-6, IL-11, and TNF-alpha, elevated N-telopeptide and deoxy-pyrrolidine, and reduced osteocalcin, suggesting that the acute inflammatory response to pulmonary exacerbations increases bone resorption and diminishes bone formation [13]. Additionally, a longitudinal study demonstrated that the frequency of IV antibiotics was inversely associated to bone mineral density as measured by DXA [14]. These data suggest that preventing pulmonary exacerbations and the associated inflammatory response protects bone health.

**Nutrition**

Maintaining adequate nutrition is another non-pharmacologic strategy to promote bone health. Numerous studies demonstrate an

---

**Table 1**

Comparison of available guideline for bone health screening and non-pharmacologic treatment with calcium and vitamin D and biochemical measurements.

| Cystic Fibrosis Foundation [11] | European (ESPEN- ESPGHAN-ECFS) Guidelines [92] | French Guidelines [93] | Australian Guidelines [94] |
|--------------------------------|-------------------------------------------------|------------------------|---------------------------|
| **Baseline Screening Bone Density** | **8 year of specific risk factors** (≤90% ideal body weight, FEV1 < 50% Predicted, Glucocorticoid >5 mg for > 3 months/year, delayed puberty, or history of fractures) OR at 18 years of age 1300-1500 mg per day (ages 9 and above) * | **8 to 10 years of age every 1-5 years** | **8 years** |
| **Vitamin D levels** | **30-60 ng/ml (75-150 nmol/L)** | **above 20 ng/ml (50 nmol/L)** |  |
| **DXA Monitoring Children** | **Z-scores** | **Z-scores** |  |
| Adults | **>−1: every 5 years** | **>−1: every 2 years** | **Every 3–5 years if bone mineral density is normal; Z or T-scores > −1** |
| | **≤−1 and > −2: every 2-4 years** | **≤−1 and > −2: every 2 years** | **Every two years if bone mineral density was moderately reduced; Z-score between −1 and −2; or T-score between −1 and −2.5** |
| | **<−2: every year** | **≤−2, and or low trauma fracture: screen every year** | **Annually if bone mineral density was severely reduced; z-score < −2 or T-score < −2.5** |
| **Biochemical Measurements** | **Serum: Albumin corrected calcium, fasting phosphate, 25(OH)D, PTH, Urinary calcium excretion, prothrombin time** | **Serum: Vitamin D, PTH, Urinary sodium : creatinine ratio – aiming for 17-52 mmol/mmol** |  |
association between poor nutrition and low aBMD in CF [13–17]. Mechanisms linking malnutrition to low bone mineral density include low calcium, vitamin D, or vitamin K, protein deficiency, and hypogonadism [18,19]. Pancreatic enzyme replacement therapy (PERT) is key to achieving nutritional goals for pancreatic insufficient patients with CF. Nutritional guidelines recommend 110–200% calories per day with 35–40% calories from fat to maintain BMI > 50 percentile for youth and > 22 or 23 kg/m2 for adult females and males respectively [20]. While these guidelines were designed to optimize pulmonary function, achieving recommended BMI targets is expected to optimize bone health as well.

**Glucocorticoids**

Glucocorticoids are a common treatment for CF pulmonary exacerbations with negative impact on bone health. Glucocorticoids stimulate bone resorption and inhibit bone growth through multiple mechanisms, including reduced IGF-1 synthesis and suppressed sex steroids [17]. Glucocorticoid treatment is associated with reduced BMD in multiple studies, though this effect is confounded by disease severity [14,16]. Avoidance of glucocorticoid therapy and use of the lowest therapeutically dose when necessary is likely to preserve BMD among PCF.

**Cystic fibrosis related diabetes**

PCF with hyperglycemia have lower muscle mass and insulin treatment is associated with gain of lost muscle suggesting insulin has an anabolic effect on the musculoskeletonal system by inhibition of proteolysis [21]. PCF with early onset diabetes tend to have lower fat percentage, lower weight, and lower leptin levels [22]. Leptin has a direct anabolic effect on osteoblasts and other indirect effects that positively impact bone health [23]. All forms of diabetes impact bone health due to insulinopenia, inflammation, and elevated advanced glycation end products [24,25]. PCF with CFRD are particularly vulnerable to reduced bone turnover with reported negative associations with fastigal glucose [26].

**Physical activity**

Engaging in physical exercise is another non-pharmacologic strategy to promote bone health among people with CF. The functional bone-muscle unit is affected in pediatric chronic illness. Muscle mass and strength increase during growth and puberty, leading to increased mechanical load on the bone, resulting in a positive change in the dimension and strength of bone. In chronic illness, decrease in lean muscle mass due to reduced mobility, pubertal delay, and glucocorticoid exposure impact bone accrual [27,28]. Earlier models of CF-related physiotherapy focused on inhalation therapy and airway clearance. With an increasing awareness of CFBD, physiotherapy has expanded to include physical education and exercise [29] with efforts directed at increasing mechanical loading to skeletal regions, above what is performed at baseline. Increase in weight bearing activity stimulates bone accrual during periods of growth as well as in adulthood [30]. While future randomized control trials (RCTs) are needed to assess a true causal relationship between increased exercise and improved bone health, multiple studies in children and adolescence point to a positive association [14,31,32]. In prepubertal and early puberty, prescribed weight-bearing exercise resulted in a gain in BMD at the femoral and lumbar spine (LS) regions of 6.6% and 5.5%, respectively. A smaller effect was noted in pubertal children, where the influence of sex and growth hormones had a stronger effect on bone mineral accrual [30]. At present, recommendations include engaging in higher impact weight bearing exercise at least 3 days per week [8,33] with an attention to adjusted nutritional targets to compensate for increased energy expenditures.

Exercise is associated with higher bone mineral density among the general population and moderate reduction in fracture risk [34]. A study of CF adults found that exercise frequency positively correlated with BMD [14]. Other studies demonstrate correlation between results of the 6-minute walk test and exercise capacity with BMD among adults with CF [16,17]. Although data regarding the impact of exercise on fracture risk in CF is lacking, physical activity has multiple other health benefits and is generally advisable. Exercise for adults promotes muscle preservation in addition to improving glucose tolerance, and reducing inflammatory cytokines [35]. Individualized, unsupervised home exercise training has shown improved fitness, and improved lung function [36]. While there are no RCTs that have directly shown benefits in CFBD, data can be extrapolated from other studies [37].

**Calcium**

Adequate calcium intake is critical during childhood and adolescence as most of the total body calcium content resides in the skeleton [38]. In CF, there are multiple factors leading to calcium deficiency, including malabsorption, increased intestinal permeability [8], increased urinary calcium excretion as a result of a high salt diet, vitamin D deficiency, and alterations in dietary intake. While most people with CF usually meet goals for calcium intake due to a high caloric diet, ongoing yearly monitoring of calcium and urinary calcium [33] and as needed supplementation should be considered. Daily recommended calcium intake for all youth to achieve a maximum net calcium balance is 250 mg/d in infants, 500 mg/d in children 1–3 years, 800 mg/d at 4–8 years, 1200–1500 mg/day at 8–10 years, and 1200–1300 mg/day for preteens and teens [38,39]. Calcium rich foods and fortified drinks are preferred over oral supplementation due to increased bioavailability and absorption [40].

Concomitant vitamin D and calcium supplementation in adults reduced the rate of bone turnover and bone loss in PCF. This choice is particularly important for women desiring pregnancy who would like to avoid the potential risks of bisphosphonates on the fetus [41]. Most studies indicate the need for a calcium intake of 1000–1200 mg of elemental calcium by means of supplementation and diet in adults [42]. The need for calcium in pregnancy and lactation is about 10–20% higher. In general, increasing calcium intake might be beneficial in reducing intestinal hyperabsorption of dietary oxalate which is known to increase the risk of urinary oxalate stones in PCF [43].

**Vitamin D**

Vitamin D deficiency is common among pancreatic insufficient individuals with CF, with 15–26% of CF patients demonstrating vitamin D deficiency (25-OH vitamin D < 20 ng/mL) and 26–90% demonstrating vitamin D insufficiency (25OH vitamin D 20–30 ng/mL) [10–13]. Typical doses of vitamin D are generally insufficient for people with CF due to persistent fat malabsorption [18]. A randomized study of UV light exposure in adults with CF to bypass intestinal absorption issues and promote natural vitamin D synthesis, failed to demonstrate significant improvement in vitamin D levels, possibly due to poor adherence [44]. Vitamin D and/or calcium deficiency can cause secondary hyperparathyroidism, which increases bone resorption with adverse consequences on bone density and strength. On the other hand, over-treatment of vitamin D deficiency has the potential to suppress PTH and reduce healthy bone turnover [6]. The US CFF guidelines recommend annual vitamin D assessment and re-assessment after vitamin dose changes [11,45]. European guidelines also recommend periodic assessment of calcium, phosphorus, PTH, and urine calcium levels [6]. Urine sodium excretion is proportional to urinary calcium loss. French guidelines further recommend urine sodium and albumin assessment [1018]. These are summarized in Table 1.

**Vitamin K**

Vitamin K is a necessary cofactor for clotting factor production as well as for the carboxylation of osteocalcin into its active form. In CF, deficiency of vitamin K results from losses (fat malabsorption, liver disease) and insufficient production (long term antibiotic use) [8,40].
There is limited evidence that supports vitamin K supplementation can improve bone mineralization [46,47] and as a result, there remains a lack of consensus on optimal daily vitamin K dose. Daily supplementation is still recommended, ranging from 0.3 to 1 mg per day, with preference for daily instead of weekly dosing due to rapid turnover [6,11]. Future RCTs in children and adults measuring DXA outcomes and coagulation effects are needed.

Secondary causes of low bone density

Evaluation of secondary causes of bone loss should be considered in cases of decreased bone mineralization. Celiac disease is an autoimmune disease affecting the small intestinal mucosa due to sensitivity to dietary gluten. This condition is known to cause metabolic bone disease [48]. Consideration should be given to serologic testing for celiac antibodies if there is severe bone disease, failure of vitamin D repletion with high vitamin D doses, or failure of antiresorptive therapy [49]. There is some recent literature linking CFTR dysfunction and celiac disease suggesting the concomitant incidence of CF and celiac disease up to 1.4% [50,51]. Hyperparathyroidism [52] and thyroid dysfunction [53] should also be ruled out in cases of failure of antiresorptive therapy.

Growth hormone (GH) and IGF-1 work at the growth plates of long bones to enhance linear growth, with the highest rates of growth occurring in infancy and puberty. Malnutrition and chronic inflammation lead to the suppression of the GH-IGF-1 axis with resulting reports of low IGF-1 levels in children and adults [54]. Glucocorticoid use, both oral and inhaled, have been implicated in further growth suppression by means of decreased GH secretion, decreased IGF-1, and direct action on chondrocytes at the growth plate [54]. Treatment with recombinant human growth hormone (rhGH) in children with CF is considered safe based on limited available data, with small trials reporting an improvement in height and trend towards increased BMC [55]. Treatment lead to the suppression of the GH-IGF-1 axis with resulting reduced and coagulation effects are needed.

Progesterone-only contraceptives are known to reduce bone formation up to age 21, but no benefit with treatment after age 21 [65]. Interestingly, treatment with exogenous estrogen does seem to improve BMC in women with CF. A study of 145 women with CF showed increase in bone mineral apparent density at the LS and hip over 12 months resulted in a significant increase in LS BMC Z-score with a mild side effect panel [71]. A 2013 randomized control trial looking at oral bisphosphonate therapy in children, adolescents, and young adults with CF (age 2–30 years) showed increase in bone mineral apparent density at the LS and hip over a 2 year period [72]. The most significant increase occurred in younger children compared to young adults. Low fracture incidence and small study sample size in these trials limit evaluation of fracture risk assessment in those who have been treated.

Denosumab

Denosumab is a monoclonal antibody directed against the receptor activator of nuclear factor kappa b ligand (RANKL). RANKL stimulates osteoclast action that break down bone. Denosumab is administered as a subcutaneous injection every 6 months. There is theoretical evidence that denosumab might be beneficial in CFBD [73] because murine models show that CFTR knockout mice osteoblasts have a higher RANKL: osteoprotogerin (OPG) ratio favoring bone loss. Use of denosumab might alter this ratio leading to benefit in CFBD. There are ongoing trials examining the effects of denosumab on CFBD. Denosumab should not be administered if there is preexisting hypocalcemia, and close post treatment monitoring of calcium is necessary for people with eGFR <30 ml/min. The other risks associated with denosumab include osteonecrosis of the jaw, atypical femoral fractures, and serious infections. Cessation of treatment with denosumab needs to be followed by alternative therapy to avoid rebound vertebral fractures [74].

Selective estrogen receptor modulators (SERM)

Raloxifene and Bazedoxifene are both selective estrogen receptor
modulators (SERMs) that are approved for prevention of postmenopausal osteoporosis [75].Raloxifene can also be used for treatment. Bazedoxifene is combined with conjugated estrogen and is approved for vasomotor symptoms of menopause. Their use in CFBD is limited to a small subset of women who are post-menopausal with intact uteri. Their use in CFBD is not widespread. The major adverse effects are an increase in venous thromboembolic events and stroke. The minor side effects include hot flashes, leg cramps and edema.

Calcitonin

Calcitonin is a nasal spray indicated for the treatment of postmenopausal osteoporosis in women >5 years post menopause when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated. Adverse effects include hypersensitivity reactions, nasal side effects such as rhinitis or epistaxis. Metanalysis data suggest an association with cancer in long term use [76].

Anabolic therapy

Anabolic agents are a group of medications that promote new bone formation [77]. There are 3 agents that are currently FDA approved for treatment of osteoporosis. There are two parathyroid hormone (PTH) analogs, Teriparatide and Abaloparatide, and one sclerostin antibody, Romozosumab.

Teriparatide is a recombinant 1–34 N-terminal active fragment of PTH. It is used in people with a high risk of fractures in postmenopausal women with osteoporosis, hypogonadal osteoporosis in men, and in sustained systemic glucocorticoid therapy. Teriparatide can be used in CFBD as a daily injection. Teriparatide activates osteoblasts and promotes new bone formation. Murine data suggest that canonical Wnt-signaling, a pathway essential for osteoblast differentiation, is not activated in CFTR [73]. Thus, teriparatide may have a blunted effect on CFBD. However, there are case reports that support the use of teriparatide but no controlled trials [78]. Abaloparatide is a synthetic analog of parathyroid hormone related peptide (PTHrp) and has a 42% homology to the PTH molecule [79]. In rodent studies, glucocorticoid use blunted the benefits of Abaloparatide with the frequency of glucocorticoid use in CF, the question of the efficacy of Abaloparatide in CFBD will require further clinical trials [79,80].

Romozosumab is a monoclonal antibody that binds sclerostin and promotes a dual action of increasing bone formation and decreasing bone resorption [81]. It is currently approved as a monthly injection at a dose of 210 mg for severe osteoporosis for 12 months. The major risk of this medication is the lack of cardiovascular safety with data indicating a risk of myocardial infarction, stroke and cardiovascular death. However, most PCF are not high risk for cardiovascular disease and may be potential candidates for therapy [82].

Management of CFBD in lung transplantation and chronic use of steroid

About 80% of people awaiting lung transplantation have abnormal bone density with 61% having osteopenia or osteoporosis [83]. Furthermore, people with CF have lower BMD than other lung transplant candidates likely due to lack of bone-active treatments, inadequate calcium supplementation, and a high degree of vitamin D deficiency [83]. PCF undergoing transplantation show improvement in trabecular bone score and LS BMD if treatment is initiated compared to transplantation for other pulmonary causes [84]. Initiation of pharmacologic therapy should be considered prior to transplantation due to significant bone loss after transplantation due to steroid administered for immunosuppression induction or prolonged immobilization.
Bone modeling pathways [87]. Importantly, application of the C18 prostaglandin E-2 (PGE-2) levels, suggesting tissue-level alteration in Elexacaftor/Tezacaftor/Ivacaftor (E/T/I) [85].

Deficient cells demonstrate increased RANK-L:OPG ratio and reduced CF bone disease [86]. CFTR is expressed in human osteoblasts and CFTR-dysfunctional CFTR in the bone or by ameliorating other risk factors for effective CFTR modulator, either with Ivacaftor or a combination of approximately 90% of people with CF can now be treated with a highly effective modulator, promoting the open position for the CFTR chloride channel. Lumacaftor, Tezacaftor, and Elexacaftor are correctors, aiding misfolded proteins to fold properly and traffic to the cell surface.

CFTR modulator therapies may improve bone density by targeting dysfunctional CFTR in the bone by or ameliorating other risk factors for CF bone disease [86]. CFTR is expressed in human osteoblasts and CFTR-deficient cells demonstrate increased RANK-L:OPG ratio and reduced prostaglandin E-2 (PGE-2) levels, suggesting tissue-level alteration in bone modeling pathways [87]. Importantly, application of the C18 corrector to cultured osteoblasts increased RANK-L and PGE-2, suggesting that CFTR modulator therapy may directly treat low BMD in people with CF [88]. CFTR modulator therapy may also indirectly improve bone health by improving nutrient absorption, hypogonadism, and pulmonary disease [86]. Clinical studies of Ivacaftor in adults with CF with at least one copy of the G511D mutation suggest some impact on BMD. Sermet-Gaudelus et al. demonstrated improvement in lumbar BMD on DXA (mean 1.1 to 1.0 (95% CI 0.4) in seven adults treated with Ivacaftor for 1–3 years [89]. A larger study by Putman et al. evaluated 28 youth and adults with DXA and quantitative CT and found no difference in BMD measured by DXA after Ivacaftor. The adult cohort did demonstrate increased cortical volume, area, and porosity of the radius and pulmonary disease [86] . Clinical studies of Ivacaftor in adults with CF with at least one copy of the G511D mutation suggest some impact on BMD. Sermet-Gaudelus et al. demonstrated improvement in lumbar BMD on DXA (mean 1.1 to 1.0 (95% CI 0.4) in seven adults treated with Ivacaftor for 1–3 years [89]. A larger study by Putman et al. evaluated 28 youth and adults with DXA and quantitative CT and found no difference in BMD measured by DXA after Ivacaftor. The adult cohort did demonstrate increased cortical volume, area, and porosity of the radius and pulmonary disease [86].

Future directions

CFBD is becoming an area of increasing focus in clinical care and research. Highly effective modulators bring a new ray of hope but their

### Table 2

| Cystic Fibrosis Related Studies | Route of administration and dose | Salient Adverse effects | Maximum Duration of therapy |
|-------------------------------|---------------------------------|------------------------|-----------------------------|
| **Bisphosphonates**          |                                 |                        |                             |
| Alendronate                   | Adults >25 kg, 35 mg weekly 70 mg weekly | Oral bisphosphonates are associated with reflux, esophagitis | 10 years and reassess       |
| Papoaannou et al. [42]        | Adults ≥25 kg, 70 mg weekly     | Intravenous bisphosphonates are associated with flu-like symptoms, arthralgia, and muscle aches | 10 years and reassess       |
| M.L. Bianchi et al. [72]      | Orally administered             | This is prominent in CF patients and some may require transient treatment with steroids. Rare side effects include osteonecrosis of the jaw and atypical femoral fractures | 10 years and reassess       |
| Risedronate                   | Children Adults                 |                        |                             |
| C.S. Haworth et al. [96]      | Orally administered             |                        |                             |
| Ibandronate                   | Children Not indicated          |                        |                             |
| Pamidronate                   | Adults Orally or intravenous administration |                        |                             |
| R.M. Aris et al. [97]         | Children 1st lifetime dose, 0.5 mg/kg (max 30 mg) | Unknown but can be used for longer periods due to short duration of action |                             |
| C.S. Haworth et al. [98]      | Subsequent doses, 1 mg/kg (max 60 mg) | 5 years and reassess |                             |
| Zoledronic acid               | Children q6-12wks               |                        |                             |
| Karahasanovic A, et al. [97]  | Adult 1V. 1st lifetime dose, 0.0125 mg/kg | 5 years and reassess |                             |
| Chapman, H. et al. [99]       | Subsequent doses, 0.025–0.05 mg/kg q6 months | 5 years and reassess |                             |
| Anabolic Bone agents          | Post-pubertal, 5 mg every 12 months | Lifelong, plan for alternative treatment needs to be formulated for denosumab cessation |                             |
| SERMs                         | Denosumab Children             | Venous thromboembolism, weight gain, edema |                             |
| Indicated for post-menopausal women | Children 1.1 to 2.5 mg/kg every 6 months | Lifelong, plan for alternative treatment needs to be formulated for denosumab cessation |                             |
| Raloxifene                    | Oral: 60 mg once daily.         |                        |                             |
| None available                | Oral: Conjugated estrogens 0.45 mg and bazedoxifene acetate 20 mg | Venous thromboembolism, weight gain, edema | Lifelong, plan for alternative treatment needs to be formulated for denosumab cessation |
| Bazedoxifene                  | None available                  |                        |                             |
| None available                |                               |                        |                             |
| Denosumab                     | Adults 1V. 5 mg every 12 months |                          |                             |
| None available                |                               |                        |                             |
| Anabolic Bone agents          | Subcutaneous 1 mg/kg every 6 months |                          |                             |
| None available                | Subcutaneous 60 mg every 6 months |                          |                             |
| Teriparatide                  | O. Siwamogsatham et al. [78]   | Short term risks include hypercalcemia, hypercalciuria, hypotension | 2-year lifetime use         |
| Abaloparatide                 | None available                  | Long term therapy has a theoretical risk of osteosarcoma | 2-year lifetime use         |
| Remosozumab                   | None available                  | Cardiovascular effects including myocardial infarction and stroke | 12 months                   |
| None available                |                                 |                        |                             |

### Potential impact of CFTR modulator

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators are a revolutionary class of medications targeting the underlying genetic defect causing CF. Ivacaftor is a small molecule potentiator, promoting the “open” position for the CFTR chloride channel. Lumacaftor, Tezacaftor, and Elexacaftor are correctors, aiding misfolded proteins to fold properly and traffic to the cell surface. Approximately 90% of people with CF can now be treated with a highly effective CFTR modulator, either with Ivacaftor or a combination of Lumacaftor/Tezacaftor/Ivacaftor (E/T/I) [85].

CFTR modulator therapies may improve bone density by targeting dysfunctional CFTR in the bone or by ameliorating other risk factors for CF bone disease [86]. CFTR is expressed in human osteoblasts and CFTR-deficient cells demonstrate increased RANK-L:OPG ratio and reduced prostaglandin E-2 (PGE-2) levels, suggesting tissue-level alteration in bone modeling pathways [87]. Importantly, application of the C18 corrector to cultured osteoblasts increased RANK-L and PGE-2, suggesting that CFTR modulator therapy may directly treat low BMD in people with CF [88]. CFTR modulator therapy may also indirectly improve bone health by improving nutrient absorption, hypogonadism, and pulmonary disease [86]. Clinical studies of Ivacaftor in adults with CF with at least one copy of the G511D mutation suggest some impact on BMD. Sermet-Gaudelus et al. demonstrated improvement in lumbar BMD on DXA (mean −1.1 to −0.4) in seven adults treated with Ivacaftor for 1–3 years [89]. A larger study by Putman et al. evaluated 28 youth and adults with DXA and quantitative CT and found no difference in BMD measured by DXA after Ivacaftor. The adult cohort did demonstrate increased cortical volume, area, and porosity of the radius and tibia on quantitative CT, but not the youth cohort [90]. Observational studies of patients taking E/T/I are ongoing and may shed further light on the impact of highly effective modulator therapies on bone health [91].
effects on mitigating CFBD are yet to be fully explored. Anabolic bone agents and Denosumab are agents that need to be better studied in CFBD. Preventative measures instituted early during childhood and adolescence will allow PCF to achieve a normal peak bone mass thus allowing a more normal trajectory for bone accrual and maintenance.

Declaration of Competing Interest

Conflict of Interest or Competing Interest: My coauthors and I do not have any conflict of interest other than the fact that 3 of us were funded by the Cystic Fibrosis Foundation.

A Declaration of Interest: there is no financial/personal interest or belief that could affect our objectivity, and there is no potential competing interests.

References

[1] Schneiberg M, Haq LJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021;397(10290):219-21.
[2] DiMango E, Spielman DB, Overdevest J, Keating C, Francis SF, Dansky D, et al. Effect of highly effective modulator therapy on quality of life in adults with cystic fibrosis. Int Forum Allergy Rhinol 2021;11(1):75-81.
[3] Mora Vallellano J, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011;10(3):134-42.
[4] Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, Burgess J, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001;12(5):366-70.
[5] Shepard S, Gemma S, Patel A. Factors associated with low bone mineral density in patients with cystic fibrosis. J Bone Miner Metab 2015;33(2):180-5.
[6] Sermet-Gaudelus I, Bianchi ML, Garbadian M, Aris RM, Morton A, Hardin DS, et al. Prevention of bone disease in children with cystic fibrosis. Bone 2021;147:115929.
[7] Sheikh S, Gemma S, Patel A. Factors associated with low bone mineral density in children and young adults with cystic fibrosis. Pediatr Pulmonol 1999;27(2):80-3.
[8] Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, Burgess J, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001;12(5):366-70.
[9] Henderson RC, Madsen CD. Bone mineral content and body composition in adult cystic fibrosis. Adv Pediatr 2015;62(1):73-8.
[10] Brien CJ, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011;10:516-23.
[11] Gordon CM, Leonard MB, Zemel BS. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 2014;17(2):219-42.
[12] Sermet-Gaudelus I, Castanet M, Retch-Bogart G, Aris RM. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev 2009;10(3):134-42.
[13] Simun GJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Stafarikas A, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 2018;54(3):223-31.
[14] Sermet-Gaudelus I, et al. Bone health in cystic fibrosis. Arch Pediatr 2009;16(6):610-8.
[15] Aris RM, Merkal PE, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90(3):1568-96.
[16] Cosman F, de Beur SJ, Leboff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int 2014;25(10):2359-81.
[17] Aris RM, et al. ADVANCE (Alendronate and Denosumab) trial: a randomised clinical trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adults with cystic fibrosis. J Cyst Fibros 2014;13(4):328-34.
[18] Elkin SL, Fairney A, Burnett S, Kemp M, Kyd P, Burgess J, et al. Vertebral deformities and low bone mineral density in adults with cystic fibrosis: a cross-sectional study. Osteoporos Int 2001;12(5):366-70.
[19] Henderson RC, Madsen CD. Bone mineral content and body composition in children and young adults with cystic fibrosis. Pediatr Pulmonol 1999;27(2):80-3.
[20] Legroux-Gerot I, et al. European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 2011;10:516-23.
[21] Gordon CM, Leonard MB, Zemel BS. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom 2014;17(2):219-42.
[22] Sermet-Gaudelus I, Castanet M, Retch-Bogart G, Aris RM. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr Respir Rev 2009;10(3):134-42.
[23] Simun GJ, Biggin A, Zacharin MR, Rodda CP, Tham E, Stafarikas A, et al. Consensus guidelines on the use of bisphosphonate therapy in children and adolescents. J Paediatr Child Health 2018;54(3):223-31.
[24] Sermet-Gaudelus I, et al. Bone health in cystic fibrosis. Arch Pediatr 2009;16(6):610-8.
[25] Farlay D, Armas LAG, Ginette E, Akhter MP, Recker RR, Boivin G. Nonenzymatic Glycation and Degree of Mineralization Are Higher in Bone From Fractured Patients With Type 1 Diabetes Mellitus. J Bone Miner Res 2016;31(3):1190-5.
Silverman SL, Chines AA, Kendler DL, Kung AWC, Teglbjærg CS, Felsenberg D, Stalvey MS, Clines KL, Havasi V, McKibbin CR, Dunn LK, Chung WJ, et al. Nasomyont N, Hornung LN, Gordon CM, Wasserman H. Outcomes following Bone Mineral Density in children and adolescents with cystic fibrosis are related to height deficits. J Clin Densitom 2008;11(4):581–9.

Elhakeem A, Frysz M, Tilling K, Tobias JH, Lawlor DA. Association Between Age at Puberty and Bone Accrual From 10 to 25 Years of Age. JAMA Netw Open 2019;2(8):e190918. https://doi.org/10.1001/jamanetworkopen.2019.8918.

Bianchi ML, Romano G, Saraifoger S, Costantini D, Limonta C, Colombo C. BMD and body composition in children and young patients affected by cystic fibrosis. J Bone Miner Res 2006;21(3):388–96.

Leite F, Friemert M, Heilmann M, Puvogel N, Smaczny C, von zur Muhlen A, et al. Sex steroids and body composition in men with cystic fibrosis. Eur J Endocrinol 2003;551–7. https://doi.org/10.1530/eje.0.140505.

Belche HM, Kliensch S, Leite F, Link TM, Nieszchlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997;82(8):2386–90.

Schram CA, Stephenson AL, Hannam TG, Tuliss E. Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women. J Clin Fibros 2015;13(4):398–402.

Wu M, Bettermann EL, Arora N, Hunt WR, McCracken C, Tangrichia V. Relationship Between Estrogen Treatment and Skeletal Health in Women With Cystic Fibrosis. Am J Med Sci 2020;360(5):581–90.

Cromer B, Bonny A, Stager M, Lazebrak R, Rome E, Ziegler J, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: A 24-month prospective study. Fertil Steril 2008;90(6):2060–7.

Mailhot G, Dion N, Farley D, Rizzo S, Bureau NJ, Jonphe V, et al. Impaired rib bone mass and quality in end-stage cystic fibrosis patients. Bone 2017;98:9–17.

Lambrechts MJ, Smith MJ, Choma TJ. Orthopedic Manifestations of Cystic Fibrosis. Orthopedics 2021;44(3):e440–5.

Dong R, Chen L, Gu Y, Han G, Yang H, Tang T, et al. Improvement in respiratory function after vertebroplasty and kyphoplasty. Int Orthop 2009;33(6):1689–94.

Conwell IS, Chung AB. Biphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2014;4. p. CD002210.

Nasmyont N, Hormung LN, Gordon CM, Wasserman H. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review. Bone 2019;121:60–7.

Bianchi ML, Colombo C, Assael BM, Dubini A, Lombardo M, Quattrucci S, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. Lancet Respir Med 2015;3(5):377–85.

Slavely MS, Clines KL, Haviasi V, McKibbin CR, Dunn LK, Chung WJ, et al. Osteoblast CFTB inactivation reduces differentiation and osteoprotegerin expression in a mouse model of cystic fibrosis-related bone disease. PloS One 2013;8(11):e80098.

Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr Osteoporos Rep 2019;17(1):8–15.

Silverman SL, Chines AA, Kendler DL, Kung AWC, Teglbjærg CS, Felsenberg D, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012;23(1):351–63.

Wells G, Chernoff J, Gilligan JP, Krause DS. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int 2016;27(1):13–9.

Estel EG, Rosen CJ. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol 2021;17(1):31–46.

Siwamogatham O, Stephens K, Tangrichia V. Evaluation of teriparatide for treatment of osteoporosis in four patients with cystic fibrosis: a case series. Case Rep Endocrinol 2014;2014:893589.

Brent MB. Abaloparatide: A Review of preclinical and clinical studies. Eur J Pharmacol 2021;909:174409.

Brent MB, Thomsen JS, Bruel A. Short-term glucocorticoid excess blunts abaloparatide-induced increase in femoral bone mass and strength in mice. Sci Rep 2021;11(1):12258.

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwiński E, Ferrari S, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med 2016;375(16):1532–43.

Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging 2020;37(11):845–55.

Cairloi E, Elfer-Vanichiar C, Morlacchi LC, Taria P, Rossetti V, Pappalaetera M, et al. Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure. Osteoporos Int 2019;30(6):1255–63.

Giorgio G, et al. Impact of bone-active drugs and underlying disease on bone health after lung transplantation: A longitudinal study. J Cyst Fibros 2021.

Gramegna A, Contarini M, Aliberti S, Casciaro R, Blasi F, Castellani C. From Ivacafort to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int J Mol Sci 2020;21(16):5882.

Tangrichia V. Correction of the Gene Defect in Cystic Fibrosis: Is It Too Late for Bone? J Clin Endocrinol Metab 2021;106(5):e259-61.

Velard F, Delion M, Le Henaff C, Guillaume G, Gangloff S, Jacquot J, et al. Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator. Am J Respir Crit Care Med 2014;189(6):746–8.

Velard F, et al. Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy? Eur J Respir 2015;45(3):845–8.

Sermet-Gaudelus I, Delion M, Durieu I, Jacquot J, Hubert D. Bone demineralization is improved by ivacafort in patients with cystic fibrosis carrying the p.Gly551Asp mutation. J Cyst Fibros 2016;15(6):e67–9.

Putman MS, Greenblatt LB, Bruce M, Joseph T, Lee H, Sawicki G, et al. The Effects of Ivacafort on Bone Density and Microarchitecture in Children and Adults With Cystic Fibrosis. J Clin Endocrinol Metab 2021;106(3):e248–61.

Nicholls DP, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, et al. PROMISE: Working with the CF community to understand emerging clinical and research needs for those treated with highly effective CFTR modulator therapy. J Cyst Fibros 2021;20(2):205–12.

Turck D, Braegger CP, Colombo C, Delecroq D, Morton A, Pancheva R, et al. ESPEN-ESPGHAN-EFCs guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016;35(3):557–77.

Sermet-Gaudelus I, et al. Recommendations for the management of bone demineralization in cystic fibrosis. Arch Pediatr 2008;15(3):301–12.

van der Haak N, King SJ, Crowder T, Kench A, Painter C, Saxby N. Highlights from ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosis. J Cyst Fibros 2020;19(1):16–77.

Aris RM, Lester GE, Caminiti M, Blackwood AD, Hendler M, Lark RK, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004;169(1):77–82.

Haworth CS, Sharples L, Hughes V, Elkin SL, Hodson ME, Conway SP, et al. ESPEN-ESPGHAN-EFCs guidelines on nutrition care for infants, children, and adults with cystic fibrosis. Clin Nutr 2016;35(3):557–77.

Aris RM, et al. Recommendations for the management of bone demineralization in cystic fibrosis. Arch Pediatr 2008;15(3):301–12.

van der Haak N, King SJ, Crowder T, Kench A, Painter C, Saxby N, Highlights from the nutrition guidelines for cystic fibrosis in Australia and New Zealand. J Cyst Fibros 2020;19(1):16–25.

Aris RM, Lester GE, Caminiti M, Blackwood AD, Hendler M, Lark RK, et al. Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 2004;169(1):77–82.